

Behavioral Health and Pediatric Primary Care (TiPS) Conference
April 9, 2021 – 8:00 AM to 4:30 PM

Presenter Bio

Rebecca Miller, MD, FAAP
Assistant Professor, Psychiatry
University of Pittsburgh School of Medicine
UPMC Children’s Hospital of UPMC
Children’s TiPS
Pittsburgh, PA

Dr. Miller earned her MD from the University of Chicago Pritzker School of Medicine. She completed her residency in Western Psychiatric/Children’s Hospital of Pittsburgh’s Triple Board Program. She was a Triple Board chief resident in her final year of residency training. She is board-certified in pediatrics, adult psychiatry and child and adolescent psychiatry.

She is an Assistant Professor of Psychiatry at the University of Pittsburgh School of Medicine, and she works as an outpatient psychiatrist at the Center for Psychiatric and Chemical Dependency Services, as a psychiatrist with the TiPS service and is the psychiatrist for the WPH Acute Adolescent Partial Hospitalization Program in Wexford

Name and Narrative Description of your Presentation.

ADHD Medications: Beyond the Basics

I will review general medication-based treatment approaches to ADHD, including stimulants, alpha agonists and atomoxetine. I will then focus on how to transition between stimulants, including within the methylphenidate and mixed amphetamine salt classes of medications, and between those two classes.

Three (3) learning objectives

By the completion of this session, participants should be able to:

1. Describe the main categories of medication-based treatment for ADHD, including stimulants, alpha-agonists and other medications.
2. Identify appropriate starting doses of stimulants
3. Covert dosages between methylphenidate medications and mixed-amphetamine salt medications, and vice versa.

Three (3) current (within the past 10 years) peer-reviewed publications that support the evidence base for the content of your presentation

1. Childress, AC. Komolova, M. Sallee, MR. (2019). An update on the pharmacokinetic considerations in the treatment of ADHD with long-acting methylphenidate and amphetamine formulations. *Expert Opinion on Drug Metabolism and Toxicology*. 15(11), 937-974.
2. Punja, S. Shamseer, L. Hartling, L. Urichuk, L. Vandermeer, B. Nikles, J. Vohra, S. (2016). Amphetamines for attention deficit hyperactivity disorder (ADHD) in children and adolescents. *Cochrane Database of Systematic Reviews*. Feb 4(2), CD009996.
3. Storebø, OJ. Ramstad, E. Krogh, HB. Nilausen, TD. Skoog, M. Holmskov, M. Rosendal, S. Groth, C. Magnusson, FL. Moreira-Maia, CR. Gillies, D. Buch Rasmussen, K. Gauci, D. Zwi, M. Kirubakaran, R. Forsbøl, B. Simonsen, E. Gluud, C. (2015). Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). *Cochrane Database of Systematic Reviews*. Nov 25(11), CD009885.